AI-Based Conversational Intervention for Early Dementia Prevention
(AI-CONECT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines how conversations with an AI program might prevent early dementia in older adults experiencing loneliness. The AI will engage in regular conversations with participants to assess its impact on their mental health. Participants will be divided into two groups: one will interact with the AI, while the other will have brief survey calls with a human. This trial suits individuals aged 75 or older who live alone, have mild memory issues, and rarely engage in long conversations. As an unphased trial, it provides a unique opportunity to explore innovative methods for enhancing mental health and reducing loneliness.
What prior data suggests that this AI-based conversational intervention is safe for early dementia prevention?
Research has shown that using AI for conversations is generally safe. A recent study found that frequent interactions with AI can lower the risk of dementia by reducing loneliness and slowing memory decline. This suggests that people typically tolerate this treatment well. Additionally, AI technology has been used to detect dementia early and assist with memory and social skills, demonstrating its safety and effectiveness in similar contexts.
No specific reports of negative effects from AI conversations have emerged. The absence of adverse outcomes in related studies further supports their safety. While more information is always beneficial, current evidence suggests this AI approach is safe and may help prevent early dementia.12345Why are researchers excited about this trial?
Researchers are excited about the AI-based conversational intervention for early dementia prevention because it offers a novel, tech-driven approach that could complement or enhance current methods. Unlike standard treatments that focus heavily on medications or lifestyle changes, this intervention uses AI to engage participants in regular, meaningful conversations. The AI agent aims to stimulate cognitive function and provide mental engagement in a way that is both scalable and personalized. This innovative approach could lead to more accessible and engaging interventions for individuals at risk of dementia, potentially slowing down cognitive decline with the help of cutting-edge technology.
What evidence suggests that this AI-based conversational intervention is effective for early dementia prevention?
Research has shown that talking with AI programs can help prevent early dementia. In this trial, participants in the AI-CONECT arm will engage in four 15- to 30-minute conversations per week with the AI agent, along with a weekly survey call with a human interviewer. Studies suggest that regular chats with an AI can lower the risk of memory problems, especially for older adults who are often alone. One study found that people who talked with an AI improved their memory and felt less depressed. Additionally, AI can assist doctors in diagnosing dementia earlier. These findings suggest that using an AI chat program might help maintain brain health and lower the risk of dementia.12356
Who Is on the Research Team?
Hiroko H Dodge, PhD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for older adults who are socially isolated and have mild problems with memory or thinking (mild cognitive impairment).Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive conversational AI-based interventions for early dementia prevention
Follow-up
Participants are monitored for changes in social self-efficacy and social engagement
What Are the Treatments Tested in This Trial?
Interventions
- AI-based conversational intervention
Trial Overview
The study is testing whether regular conversations with an AI-based system can help prevent early dementia in socially isolated seniors. Participants are randomly assigned to either use the conversational AI or not.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants will receive four 15- to 30-minute conversations per week with the AI agent and a weekly 10- to15-minute survey call with a human interviewer.
Participants will receive a weekly 10- to 15-minute survey call with a human interviewer.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Arizona State University
Collaborator
Citations
Harnessing artificial intelligence for transforming dementia ...
Findings indicate that AI significantly improves the accuracy and timeliness of dementia diagnoses, often detecting early-stage disease with greater precision ...
Conversational AI in Cognitive and Social Training for ...
Conversational AI shows directional benefit across cognitive, social, and caregiver outcomes. Critical research gaps remain regarding voice-only randomized ...
Beneficial effect of artificial intelligence care call on ...
Our first major finding was that after 31 weeks of the CLOVA CareCall intervention, the GDS scores decreased, and memory scores increased.
A-CONECT: Designing AI-based Conversational Chatbot ...
A recent clinical trial showed that frequent conversation is an effective dementia risk-reduction strategy against social isolation and cognitive decline.
Effectiveness of AI-based conversational and socially assistive ...
AI-based conversational and socially assistive agent interventions appear to be effective in reducing depressive symptoms among older adults,
Using Artificial Intelligence–Based Technologies for the Early ...
Artificial intelligence–based technologies (AITs) have the potential to support earlier detection of the behavioral and psychological symptoms ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.